Radcliffe Capital Management L.P. Has $3.99 Million Holdings in Oaktree Acquisition Corp. III Life Sciences $OACC

Radcliffe Capital Management L.P. increased its holdings in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) by 67.1% during the fourth quarter, Holdings Channel reports. The fund owned 377,065 shares of the company’s stock after purchasing an additional 151,403 shares during the period. Radcliffe Capital Management L.P.’s holdings in Oaktree Acquisition Corp. III Life Sciences were worth $3,989,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Clear Street Group Inc. acquired a new stake in Oaktree Acquisition Corp. III Life Sciences during the 3rd quarter valued at $231,000. Readystate Asset Management LP acquired a new position in Oaktree Acquisition Corp. III Life Sciences in the third quarter worth $262,000. UBS Group AG grew its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 987,110.0% during the third quarter. UBS Group AG now owns 98,721 shares of the company’s stock worth $1,038,000 after purchasing an additional 98,711 shares during the last quarter. Verition Fund Management LLC grew its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 6.7% during the third quarter. Verition Fund Management LLC now owns 161,740 shares of the company’s stock worth $1,693,000 after purchasing an additional 10,117 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the second quarter valued at $2,094,000.

Oaktree Acquisition Corp. III Life Sciences Price Performance

OACC opened at $10.76 on Wednesday. The company’s 50 day simple moving average is $10.67 and its 200-day simple moving average is $10.64. Oaktree Acquisition Corp. III Life Sciences has a one year low of $10.30 and a one year high of $10.74.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last posted its quarterly earnings data on Thursday, March 26th. The company reported $0.08 earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a report on Thursday, April 2nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Profile

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.